Comparison
BPC-157 vs. Exenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
141758-74-9
Molecular weight
1419.5 g/mol
4186.6 g/mol
Half-life
4 h
2.4 h
Sequence
GEPPPGKPADDAGLVHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
5
of which in humans
0
4
Effects recorded
4
3
Open conflicts
2
1
Documented adverse events
2
2